Navigation Links
ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:6/3/2008

SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it presented objective response rate and available safety data from the Company's Phase 2 clinical study of ANX-510, or CoFactor(R), for the treatment of advanced breast cancer at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL. CoFactor plus 5-FU (5-Fluorouracil) was determined to be a safe, well-tolerated and active treatment regimen in advanced breast cancer patients who are Herceptin receptor (Her2/neu) negative and who have failed prior taxane and anthracycline therapies. Data available from 31 patients indicated a 23% objective response rate with CoFactor plus 5-FU based on investigators' assessments. Objective response rate was based on the number of complete responses and partial responses observed in this study.

The poster presentation, entitled "5,10 methylenetetrahydrofolic acid with 5-fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase 2 study," was presented by Dr. Joachim P.H. Schupp, Vice President of Medical Affairs on June 2, 2008.

Historically, capecitabine (Xeloda(R)), a widely-used treatment for advanced breast cancer, has demonstrated response rates between 14% and 26% when studied as monotherapy in patients with advanced breast cancer who failed prior treatment with anthracyclines and taxanes. In this well-defined study population, two recently published, Phase 3 clinical trials, where capecitabine was the approved therapy, demonstrated response rates of 14% for capecitabine alone compared with 35% for capecitabine in combination with ixabepil
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company plc ... the Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder ... "Our views of Mylan,s offer to Perrigo ... based on our Board,s careful reflection of the value ... the limited choices that Mylan has allowed its shareholders ...
(Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic Acids, ... by Region ( North America , ... of the World) - Global Trends and Forecast to 2020", ... at USD 4.62 Billion in 2014 and is projected to ... 7.4% from 2015 to 2020. Browse 77 ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... , , INDIANAPOLIS, July 22 ... during a lease signing event that it has become the first ... Technology at East River Science Park, a development that shows tangible ... for biopharmaceutical research. The biotech park -- located adjacent to the ...
... , , MENLO PARK, Calif., ... BlueShield has adopted a positive coverage policy for the measurement ... determined that the published, peer-reviewed evidence is sufficient to support ... July 20, 2009, states the measurement of exhaled nitric oxide ...
Cached Medicine Technology:Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs 2Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs 3Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs 4Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs 5CareFirst BCBS Covers eNO Measurement for Diagnosis, Asthma Treatment 2
(Date:8/28/2015)... ... 2015 , ... An article published August 19th by the LA ... through to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior ... but the current process, having already gone on for over a year, is taking ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for the ... USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk to ... that together, a difference can be made. Walkers can participate in the cause and ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... As ... from Merz, received FDA clearance for results that last for two years, the ... exciting news for patients who are looking for a long-lasting, effective solution for their ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, ... the “Music With A Mission” benefit concert in Mendon, IL. Held in the Show ... money to support music education programs in the underfunded local school districts of Mendon ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... grams of high grade protein with zero fat, carbs, sugar, gluten, lactose or ... named a finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , Five ...
Breaking Medicine News(10 mins):Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... 10 U.S. adults suffer chronic pain that lasts a year or ... a record average of just short of 80 years, according to ... Disease Control and Prevention. ,The CDC said, 'At birth, ... 75 for males. The gap in life expectancy between white and ...
... of influenza viruses found in birds with the avian virus ... to researchers indicating pandemic strains// of bird flu. ... of the journal Nature which illustrates the genetic changes required ... enough to recognize the receptors on human cells. ...
... Alpha-1-antitrypsin deficiency, a genetic disorder, know that they shouldn't ... increased risk for// developing emphysema at a young age. ... patients with alpha-1-antitrypsin (AT) deficiency could develop serious liver ... (NSAIDs). ,A new research performed at Washington ...
... them alleviate symptoms like forgetting, distracted, impulsive or fidgety ... University Medical Center// investigates whether these symptoms of Attention ... ,If that is the case, will ... help people quit smoking – the patch with counseling ...
... childcare worker should be trained in how to handle ... today.// ,'The AMA is calling on all State ... for people who work with children,' Dr Haikerwal said. ... for anaphylactic shock, including how to use auto-injecting devices ...
... Court was notified on Wednesday by the State government ... fake doctors //in the State of Maharashtra. ,Following ... against a fraudulent doctor by a Govandi resident, Mariappa ... while under the treatment of an unqualified bogus doctor. ...
Cached Medicine News:Health News:Scinetists Alert to Onset of Pandemic through Bird flu Mutations to Humans 2Health News:Non-Steroidal Anti-Inflammatory Drugs Can Cause Liver Damages 2Health News:Non-Steroidal Anti-Inflammatory Drugs Can Cause Liver Damages 3Health News:A New Study To Examine ADHD's Role In Smoking 2
... The Model 130 has expanded memory capabilities ... has memory to retain oxygen saturation and pulse ... modes to best suit your needs:, ,1. ... minutes of information for a single patient, making ...
... Oximeter provides SpO 2 and pulse rate ... The device is battery or AC powered, has ... audible alarm signals, and an infrared link to ... is also available for added protection. The ...
... The FingerPrint Pulse Oximeter is ... with an integral printer. A ... 2 and pulse rate measurements, ... on 4 AA alkaline batteries, and ...
... oximetry monitoring system compatible with personal ... Extremely rugged and cost-effective.The BCI 3301 ... delivers pulse oximetry wherever spot-checking is ... clinics and hospitals. In fact, its ...
Medicine Products: